Supporting data for "Characterization of Chinese medicine celastrol and celastrol-loaded biodegradable nanoparticles towards the therapy of obesity and non-alcoholic fatty liver disease"

Obesity and non-alcoholic fatty liver disease (NAFLD) are hallmarked by aberrant lipid accumulation, persistent chronic inflammation and hyperactive endoplasmic reticulum (ER) stress. Warburg effect of aerobic glycolysis in hepatic M1 macrophages is a major cause for metabolic dysfunction and inflammatory stress NAFLD. Plant-derived triterpene celastrol markedly inhibited macrophage M1 polarization and adipocyte hypertrophy in obesity. The present study was designed to identify the celastrol-bound proteins which reprogrammed metabolic and inflammatory pathways in M1 macrophages. On the other hand, as a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications. The present study was designed to develop a biocompatible albumin-based nanoparticle carrier system for the controlled release of celastrol and targeted delivery in obesity and NAFLD mice. <br> The results demonstrated that celastrol might alleviate lipid accumulation, inflammation and fibrosis in the liver via covalent modification of PKM2. Meanwhile, the results indicated that albumin-based nanoparticles may be a general biocompatible drug carrier system for the controlled release of hydrophobic compounds (e.g., celastrol) for the treatment of obesity and NAFLD. This dataset contains the data from experimental results.